Apellis Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Apellis Pharmaceuticals's estimated annual revenue is currently $256.3M per year.
- Apellis Pharmaceuticals received $60.0M in venture funding in August 2017.
- Apellis Pharmaceuticals's estimated revenue per employee is $305,083
- Apellis Pharmaceuticals's total funding is $168.5M.
- Apellis Pharmaceuticals's current valuation is $3.9B. (January 2022)
Employee Data
- Apellis Pharmaceuticals has 840 Employees.
- Apellis Pharmaceuticals grew their employee count by 9% last year.
Apellis Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder, CEO & President | Reveal Email/Phone |
2 | Executive Director, Global Business Development & Head Alliance Management | Reveal Email/Phone |
3 | SVP, Head Rare Disease | Reveal Email/Phone |
4 | VP, Global Market Access, Commercial Strategy & Training | Reveal Email/Phone |
5 | Head Hematology Engagement | Reveal Email/Phone |
6 | Head Corporate & Portfolio Strategy | Reveal Email/Phone |
7 | SVP, North America Commercial | Reveal Email/Phone |
8 | VP, Biostatistics | Reveal Email/Phone |
9 | Head Development - Neurology | Reveal Email/Phone |
10 | VP, Head Total Rewards | Reveal Email/Phone |
Apellis Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $2.6M | 17 | 6% | N/A | N/A |
#4 | $4.3M | 28 | -32% | N/A | N/A |
#5 | $499.4M | 3222 | 3% | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $3.6M | 23 | 28% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $4M | 26 | 18% | N/A | N/A |
#10 | $31.8M | 205 | -14% | N/A | N/A |
What Is Apellis Pharmaceuticals?
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$168.5M
Total Funding
840
Number of Employees
$256.3M
Revenue (est)
9%
Employee Growth %
$3.9B
Valuation
N/A
Accelerator
Apellis Pharmaceuticals News
Technical analysis trends APELLIS PHARMACEUTICALS, INC. Short Term, Mid-Term, Long Term. Trends, Bullish, Bullish, Neutral...
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of...
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of...
Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspa ...
Other Companies in Crestwood
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 974 | 6% | N/A |
#2 | $1637.3M | 3544 | 10% | N/A |
Apellis Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-12-03 | $33.0M | Undisclosed | Morningside Ventures | Article |
| 2016-01-11 | $32.0M | Undisclosed | Article | |
| 2016-02-15 | $47.0M | D | Cormorant Asset Management | Article |
| 2017-08-11 | $60.0M | E | Sectoral Asset Management | Article |